Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study.

Journal Article (Journal Article;Multicenter Study)

STUDY OBJECTIVE: To assess the effect of armodafinil on task-related prefrontal cortex activation using functional magnetic resonance imaging (fMRI) in patients with obstructive sleep apnea (OSA) and excessive sleepiness despite continuous positive airway pressure (CPAP) therapy. METHODS: This 2-week, multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-group study was conducted at five neuroimaging sites and four collaborating clinical study centers in the United States. Patients were 40 right-handed or ambidextrous men and women aged between 18 and 60 years, with OSA and persistent sleepiness, as determined by multiple sleep latency and Epworth Sleepiness Scale scores, despite effective, stable use of CPAP. Treatment was randomized (1:1) to once-daily armodafinil 200 mg or placebo. The primary efficacy outcome was a change from baseline at week 2 in the volume of activation meeting the predefined threshold in the dorsolateral prefrontal cortex during a 2-back working memory task. The key secondary measure was the change in task response latency. RESULTS: No significant differences were observed between treatment groups in the primary or key secondary outcomes. Armodafinil was generally well tolerated. The most common adverse events (occurring in more than one patient [5%]) were headache (19%), nasopharyngitis (14%), and diarrhea (10%). CONCLUSIONS: Armodafinil did not improve fMRI-measured functional brain activation in CPAP-treated patients with OSA and excessive sleepiness. STUDY REGISTRATION: Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea.

Full Text

Duke Authors

Cited Authors

  • Greve, DN; Duntley, SP; Larson-Prior, L; Krystal, AD; Diaz, MT; Drummond, SPA; Thein, SG; Kushida, CA; Yang, R; Thomas, RJ

Published Date

  • February 15, 2014

Published In

Volume / Issue

  • 10 / 2

Start / End Page

  • 143 - 153

PubMed ID

  • 24532997

Pubmed Central ID

  • PMC3899316

Electronic International Standard Serial Number (EISSN)

  • 1550-9397

Digital Object Identifier (DOI)

  • 10.5664/jcsm.3440


  • eng

Conference Location

  • United States